Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumab
09:13am, Tuesday, 17'th Dec 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions
08:38am, Wednesday, 04'th Dec 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to addi
Tiziana Life Sciences secures grant for ALS trial
08:47am, Tuesday, 19'th Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Progr
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
08:18am, Saturday, 02'nd Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combinati
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
04:31pm, Friday, 01'st Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collab
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy
08:29am, Thursday, 31'st Oct 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
10:29pm, Wednesday, 30'th Oct 2024
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the opt
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
10:14am, Wednesday, 30'th Oct 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which
Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research
09:01am, Thursday, 19'th Sep 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer
Tiziana Life Sciences names new chief executive
08:53am, Monday, 19'th Aug 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. T
Tiziana Life Sciences Appoints New Chief Executive Officer
07:00am, Monday, 19'th Aug 2024
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab
09:40am, Wednesday, 24'th Jul 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formula
Tiziana Life Sciences Granted FDA Fast Track Designation
07:00am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences secures $3.4M in non-dilutive funding
11:34am, Friday, 28'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that f
